NEWS

TRICOPHARMING RAISES €480.000 IN A NEW FINANCING ROUND

150 150 marketing

We are grateful and proud to announce that we closed a new financing round last month. We would like to welcome the new partners joining Tricopharming’s capital, PedroDiazMontañez and the two investment funds, KiraVentures and Sancus Capital, which we met thanks to the program organized by Decelera Ventures in September 2021.  In addition to the…

read more

WE ARE BENEFICIARIES OF THE NEOTEC PROGRAM

150 150 marketing

Finally we can announce that we are on the official list of beneficiaries of the NEOTEC program of the Center for Industrial Technological Development CDTI and the Ministry of Science and Innovation. This program gives a boost to technology startups like ours to continue growing and developing our projects MAPStimulants and Artennua®. Thanks to this…

read more

TRICOPHARMING AND SEQUENTIA JOIN FOR INTEGRATED SOLUTIONS

150 150 marketing

We joined with Sequentia Biotech, to integrate our workflows and provide an end to end solution for research and development of biostimulants. We take care from field testing to bioinformatics analysis, to test and analyze the effectiveness of an already existing biostimulant, or an in-house tailored made to fit your needs.

read more

LEARN MORE ABOUT ARTEMISIA ANNUA AND OUR OPTIMIZED VERSION, ARTENNUA®

150 150 marketing

Artemisia annua is an aromatic herbaceous plant native to Asia, a species that stands out from the rest of its genus as an excellent and important source of clinically proven therapeutic compounds. Artemisia annua L. produces a range of complex terpenoids in its trichomes, among which artemisinin is of particular interest for the treatment of…

read more